Equities research analysts expect that Vital Therapies, Inc. (NASDAQ:VTL) will report earnings per share of ($0.31) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Vital Therapies’ earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.32). Vital Therapies reported earnings of ($0.30) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 3.3%. The business is scheduled to report its next quarterly earnings report on Tuesday, August 1st.

According to Zacks, analysts expect that Vital Therapies will report full year earnings of ($1.54) per share for the current year, with EPS estimates ranging from ($2.28) to ($1.25). For the next financial year, analysts forecast that the company will report earnings of ($1.31) per share, with EPS estimates ranging from ($1.42) to ($1.19). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Vital Therapies.

Vital Therapies (NASDAQ:VTL) last issued its quarterly earnings data on Tuesday, May 9th. The company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.02. During the same quarter in the previous year, the company posted ($0.31) EPS.

Several equities research analysts have recently weighed in on VTL shares. BTIG Research reaffirmed a “hold” rating on shares of Vital Therapies in a report on Friday, March 10th. Zacks Investment Research lowered shares of Vital Therapies from a “hold” rating to a “sell” rating in a report on Saturday, March 11th. Raymond James Financial, Inc. started coverage on shares of Vital Therapies in a report on Thursday, May 18th. They issued an “outperform” rating and a $6.00 target price on the stock. Finally, ValuEngine lowered shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $8.00.

Shares of Vital Therapies (NASDAQ:VTL) traded down 3.33% during mid-day trading on Friday, reaching $2.90. 184,709 shares of the company traded hands. The stock’s market capitalization is $122.40 million. Vital Therapies has a 52-week low of $2.25 and a 52-week high of $7.46. The stock’s 50 day moving average is $3.18 and its 200 day moving average is $4.15.

In other news, Chairman Terence E. Winters bought 10,000 shares of the stock in a transaction dated Wednesday, June 14th. The shares were acquired at an average price of $3.10 per share, with a total value of $31,000.00. Following the acquisition, the chairman now owns 194,966 shares in the company, valued at $604,394.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Muneer A. Satter bought 20,000 shares of the stock in a transaction dated Wednesday, June 7th. The stock was purchased at an average cost of $3.20 per share, for a total transaction of $64,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 3,858,400 shares of company stock worth $15,338,153. 29.88% of the stock is owned by insiders.

Large investors have recently modified their holdings of the company. FMR LLC raised its stake in shares of Vital Therapies by 102.9% in the first quarter. FMR LLC now owns 2,957,878 shares of the company’s stock worth $11,832,000 after buying an additional 1,500,000 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Vital Therapies by 9.6% in the first quarter. Victory Capital Management Inc. now owns 2,549,439 shares of the company’s stock worth $10,197,000 after buying an additional 222,824 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Vital Therapies by 1.6% in the first quarter. Vanguard Group Inc. now owns 845,858 shares of the company’s stock worth $3,383,000 after buying an additional 13,654 shares in the last quarter. State Street Corp raised its stake in shares of Vital Therapies by 6.0% in the fourth quarter. State Street Corp now owns 328,091 shares of the company’s stock worth $1,427,000 after buying an additional 18,645 shares in the last quarter. Finally, UBS Oconnor LLC bought a new stake in shares of Vital Therapies during the first quarter worth approximately $800,000. 26.62% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Analysts Expect Vital Therapies, Inc. (VTL) Will Post Earnings of -$0.31 Per Share” was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/06/16/analysts-expect-vital-therapies-inc-vtl-will-post-earnings-of-0-31-per-share.html.

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Get a free copy of the Zacks research report on Vital Therapies (VTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.